Comparative Real-World Outcomes of Chimeric Antigen Receptor T-Cell Therapy vs Standard Systemic Therapy in Diffuse Large B-Cell Lymphoma (SOHO 2026) - Sep 1, 2026 - Abstract #CT-311; Location: LEVEL 3, HALL B3; "Patients: Adults (≥18 years) with DLBCL receiving CAR-T therapy were compared with those receiving non–CAR-T systemic therapies, including polatuzumab vedotin, tafasitamab, lenalidomide, bendamustine, platinum- or gemcitabine-based regimens, selinexor, or loncastuximab tesirine. In this large real-world propensity-matched cohort, CAR-T therapy was associated with higher long-term mortality and increased healthcare utilization compared with standard therapy. These findings likely reflect differences in patient selection, disease burden, and treatment-related toxicity. Increased ICU utilization and infections highlight the need for improved risk stratification and optimized supportive care in patients undergoing CAR-T therapy."
CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin's Lymphoma • Oncology
|
|
Muzammil Dastagir MD 1; Sameeha Abdulwali MD 2
|